Purpose: The aim of our study was to assess diagnostic accuracy of Tc-99m depreotide and Tc-99m-EDDA/HYNIC-TOC scintigraphy for evaluation of pulmonary lesions that appeared ambiguous on computed tomography (CT). Material and Methods: Forty-nine consecutive patients (37 men and 12 women; mean age, 60 Ϯ 11 years) with 60 pulmonary lesions on chest radiography and CT were referred for nuclear imaging. They were prospectively allocated to undergo whole-body scintigraphy (WBS) and single photon emission computed tomography (SPECT) using either Tc-99m depreotide (26 patients, group 1) or Tc-99m-EDDA/HYNIC-TOC imaging (23 patients, group 2). Histologic findings after tissue biopsy served as a gold standard for determining diagnostic accuracy of the 2 somatostatin analogs. Visual assessment was complemented by semiquantitative analysis based on target to background ratio. Results: Among the 32 pulmonary lesions scanned with Tc-99m depreotide, focal uptake was increased in 22 of 25 malignancies, whereas no uptake was found in 6 of 7 benign lesions (88% sensitivity, 85% specificity, and 88% accuracy) on both WBS and SPECT. Imaging of 28 pulmonary lesions with Tc-99m-EDDA/HYNIC-TOC had a similar diagnostic yield (sensitivity 87%, specificity 84%, and accuracy 86%). Overall, target to background ratios were higher on SPECT than WBS but not significantly different between groups 1 and 2 (SPECT 2.72 Ϯ 0.70 vs. 2.71 Ϯ 0.50, WBS 1.61 Ϯ 0.32 vs. 1.62 Ϯ 0.28, respectively).
Recent advances in functional nuclear medicine imaging have broadened the spectrum of available methods for diagnosis of pulmonary lesions. For example, receptor scintigraphy has emerged as a more specific method that may be particularly useful in uncertain cases. 6 This approach takes advantage of a high expression of somatostatin receptors (SSTRs) in the primary neuroendocrine tumors of lungs, as well as in the small cell (SCLC) and some non-small cell lung cancers (NSCLC). [7] [8] [9] [10] Accordingly, various somatostatin analog radiopharmaceuticals have been developed, including radioiodine-labeled somatostatin analog and 111-indiumpentetreotide. 11 They were shown useful for evaluation of solitary lesion in the lungs and early detection of malignances. [12] [13] [14] Various technetium (Tc-99m)-labeled somatostatin analogs have been introduced to clinical practice during the past decade. Tc-99m depreotide has been approved by the US Food and Drug Administration for evaluation of solitary pulmonary nodules 15, 16 ). On the other hand, hydrazinonicotinamide (HYNIC) has recently proven useful as a bifunctional chelator for Tc-99m labeling of octreotide and Tyr 3 -octreotide (TOC) with high efficiency. 17 Its favorable clinical profile has been attained when ethylene diamine diacetic acid (EDDA) was used as coligand, thereby introducing Tc-99m-EDDA/HYNIC-TOC as a new somatostatin analog. 18 A few reports have indicated the potential value of Tc-99m-EDDA/ HYNIC-TOC for evaluating malignant tumors that express somatostatin receptors, especially subtype 2. 19 -21 However, to date, only one small study compared the utility of Tc-99m depreotide and Tc-99m-EDDA/HYNIC-TOC scintigraphy for differential diagnosis of solitary pulmonary nodules and suggested the need for further investigations. 22 The main purpose of this study was to assess the diagnostic utility of Tc-99m depreotide and Tc-99m-EDDA/HYNIC-TOC scintigraphy for evaluation of radiologically uncertain pulmonary lesions. The specific aims were (1) to establish diagnostic accuracy of each somatostatin analog in comparison with the biopsy findings, (2) to determine whether diagnostic accuracy differs between the 2 somatostatin analogs, and (3) to compare the uptake of Tc-99m depreotide and Tc-99m-EDDA/HYNIC-TOC in different lung lesions.
SUBJECTS AND METHODS

Subjects
The study sample included 49 consecutive patients referred for nuclear imaging of pulmonary lesions. They were 37 men and 12 women (mean age, 60 Ϯ 11 years; range, 36 -78 years). The inclusion criteria were (1) age Ͼ18 years, (2) evidence of lung lesion on plain radiograph and CT scan, and (3) lesion smaller than 6 cm of round or ovoid shape. Exclusion criteria were pulmonary lesions with benign radiologic characteristics or with highly suspicious malignant characteristics (larger than 6 cm, lung tissue infiltration, irregular margins), as well as contraindications for tissue biopsy required for pathologic verification. Chest radiography and CT revealed 60 pulmonary lesions in these 49 patients (mean size, 2.9 Ϯ 1.1 cm; range, 1.2-5.8 cm).
Patients were prospectively allocated to undergo whole-body scintigraphy (WBS) and single photon emission computed tomography (SPECT) using either Tc-99m depreotide or Tc-99m-EDDA/ HYNIC-TOC imaging, taking into account the results of tissue biopsy (malignant vs. benign, histologic type of tumor) and the size of the lesion on CT. The investigator responsible for allocating a patient to a given group was not the one who read the images. These roles were divided among 4 nuclear medicine specialists.
Group 1 included 26 patients (mean age, 60 Ϯ 10 years; range, 37-79 years; 19 men and 7 women) who underwent WBS and SPECT of the thorax with Tc-99m depreotide. Group 2 consisted of 23 patients (mean age, 61 Ϯ 12 years; range, 36 -77 years; 18 men and 5 women) who underwent WBS and SPECT with Tc-99m-EDDA/HYNIC-TOC. Histologic results of tissue biopsy served as a gold standard for determining diagnostic accuracy of each somatostatin analog. The study was approved by the ethics committee of our institution, and all patients enrolled into the study gave written informed consent.
Imaging Protocol
WBS and chest SPECT scans were performed in turn 3 hours after administration of 740 MBq (20m Ci) of Tc-99m depreotide (group 1) or Tc-99m-EDDA/HYNIC-TOC (group 2). Data were acquired using single-head gamma camera (Siemens, e.cam, Siemens Medical Solutions USA Inc., Hoffman Estates, IL). A generalpurpose collimator and an image matrix of 512 ϫ 1024 pixels were used for WBS. SPECT was acquired in 64 projections (each lasting 30 seconds) with a matrix size of 128 ϫ 128 pixels.
Image Reconstruction and Analysis
Reconstruction of tomographic images was performed using e.soft software (Siemens Medical Solutions USA Inc.) by the iterative method ordered subsets expectation maximization (OSEM). Whole-body and SPECT images were first evaluated visually by 2 experienced nuclear medicine specialists, who arrived to an agreement in case of discrepant findings. Visual appearance of an increased focal uptake of the tracer in the suspected lesion site was considered a positive finding, which served as a basis for determining (aim 1) and comparing (aim 2) diagnostic accuracy of WBS and SPECT imaging. Subsequent semiquantitative analysis was limited to positive findings where the uptake of Tc-99m depreotide or Tc-99m-EDDA/HYNIC-TOC into the lesion was compared with the nonlesion lung tissue (aim 3). For that purpose, the target to background (T/Bg) ratio was calculated after drawing the irregular region of interest around the lesion and at the corresponding contralateral area on both WBS and SPECT images.
Statistical Analysis
Statistical program SPSS (version 15, SPSS, Chicago, IL) for Windows was used for analysis. The receiver operating characteristic (ROC) analysis was used to determine sensitivity, specificity, and accuracy, which were computed with the corresponding 95% confidence intervals (95%CI), as per aim 1. In addition, z test was used to determine whether diagnostic accuracy of each analog is different from a chance (ie, area under the ROC curve different from 0.5). For aim 2, the diagnostic utility of 2 somatostatin analogs was compared using the Mann-Whitney statistic, which evaluates the probability of ranking a randomly chosen positive result higher than a randomly chosen negative result. Student t test was used to compare T/Bg ratios derived from whole-body and SPECT images between malignant and benign uptake within each group as well as between the groups (aim 3). Data are presented as mean Ϯ SD. P Ͻ 0.05 was considered statistically significant.
RESULTS
Tc-99m Depreotide Imaging (Group 1)
Among 26 patients in group 1, there were 32 pulmonary lesions on CT (1 lesion in 20 cases and 2 lesions in 6 cases). The size of the lesions, measured as the average of 2 largest dimensions on CT, was 2.6 Ϯ 1.2 cm (range, 1.2-5.8 cm). Among these, 24 (75%) solitary pulmonary nodules were smaller than 3 cm and 8 (25%) pulmonary masses were larger than 3 cm. Overall, 25 lesions (78%) proved to be malignant, whereas the remaining 7 (22%) were benign. Table 1 summarizes the histology of lesions in group 1.
The identical lesions showed increased uptake of Tc-99m depreotide on visual examination of WBS and SPECT images. Increased focal uptake was found in 22 of 25 malignant lesions (true-positive results) (Fig. 1) . Three false-negative nodules originated from 2 metastases of renal cell carcinoma ( Fig. 2 ) and 1 adenocarcinoma (mean diameter of 1.2 cm on CT).
Of the 7 benign lesions, 6 showed no uptake of Tc-99m depreotide (true-negative cases), whereas 1 inflammatory pseudotumor showed moderately increased uptake (false-positive result) (Fig.  3) . Accordingly, the results indicate 88% sensitivity (95% CI, 69%-95%), 85% specificity (42%-99%), and 88% accuracy (59%-96%) of Tc-99m depreotide scintigraphy for characterization of indeterminate pulmonary lesions. The area under the ROC curve was 0.87 (95%CI, 0.70%-0.96%), which significantly differed from chance (P Ͻ 0.001) (Fig. 4) .
The results of semiquantitative analysis of increased uptake of Tc-99m depreotide are shown in Table 2 . T/Bg ratio was significantly higher on SPECT in comparison with WBS images (2.72 Ϯ 0.70 vs. 1.61 Ϯ 0.32, P Ͻ 0.001). Also, T/Bg ratios were significantly higher in malignant than benign lesions for both WBS and SPECT (Table 3) .
Tc-99m-EDDA/HYNIC-TOC Imaging (Group 2)
Among the 23 patients in group 2, there were 28 pulmonary lesions (1 in 18 patients and 2 in 5 patients). The average size was 2.8 Ϯ 1.1 cm (range, 1.3-5.7 cm). Solitary pulmonary nodules accounted for 20 lesions and pulmonary masses for 8. Twenty-two lesions were malignant, whereas 6 were benign (Table 4) . Increased uptake of Tc-99m-EDDA/HYNIC-TOC was seen on both WBS and SPECT in 19 of 22 lesions (Fig. 1) . The 3 false-negative findings were due to 1 adenocarcinoma (diameter, 1.3 cm) (Fig. 5 ) and 2 metastases of rectal adenocarcinoma. None of the 5 benign lesions showed uptake of Tc-99m-EDDA/HYNIC-TOC (true negative), whereas the uptake was mild in 1 tuberculoid granuloma (false-positive finding) (Fig. 6 ). Overall sensitivity of Tc-99m-EDDA/HYNIC-TOC WBS and SPECT had 87% sensitivity (95% CI, 65-97%), 84% specificity (36 -99%), and 86% accuracy (56 -96%). The area under the ROC curve was 0.85 (95% CI, 0.66%-0.96%), which also significantly differed from chance (P Ͻ 0.001) (Fig. 4) .
T/Bg ratio in this group was also significantly higher on SPECT than on WBS (2.71 Ϯ 0.50 vs. 1.62 Ϯ 0.28, P Ͻ 0.001) (Fig.  7) ( Table 2) . T/Bg ratios were significantly higher in malignant than in benign lesions on WBS or SPECT images (Table 3) .
Comparison Between Somatostatin Analogs
The diagnostic accuracy of the 2 somatostatin analogs was comparable, as indicated by virtually complete overlap of the respective 95% CIs (Fig. 4) and formally confirmed by the nonsignificant result of Mann-Whitney U test. Nevertheless, visual examination of WBS and SPECT images revealed some differences in the appearance and degree of Tc-99m depreotide and Tc-99m-EDDA/ HYNIC-TOC uptake into different body structures. Tc-99m depreotide images showed relatively greater accumulation in bone marrow (sternum, ribs, and spine) and did not accumulate in the heart region (photopenic). The accumulation of Tc-99m-EDDA/ HYNIC-TOC in the blood pool of the heart appeared virtually the same as or higher than in the lungs (Fig. 1) .
DISCUSSION
This study used an overexpression of somatostatin receptors on lung cancer cells to examine diagnostic utility of 2 somatostatin analog tracers for in vivo diagnosis of pulmonary lesions that could not be diagnosed with certainty by CT. The results revealed high and comparable accuracy of Tc-99m depreotide and Tc-99m-EDDA/ HYNIC-TOC for diagnosis of indeterminate pulmonary lesions, regardless of whether these were assessed by WBS or SPECT imaging. Although the degree of uptake did not differ between the 2 traces, it was overall greater on SPECT than WBS images and in the malignant than benign tissue.
The 2 somatostatin analogs used in this study differ in their affinity for somatostatin receptor types (SSRTs). Although Tc-99m depreotide has a high affinity for SSRT2, 3, and 5, Tc-99m-EDDA/ HYNIC-TOC shows a high affinity for SSRT2 and lower affinity for SSRT5. 8, 15, 23 Therefore, the main difference between the 2 traces is in the affinity for SSRT3, which has been proposed useful for in vivo imaging of various malignant tumors, such as NSCLCs. 8 Other studies, however, were unable to confirm the role of SSRT3 for imaging of NSCLC owing to unknown incidence of their expression in human tumors. 23, 24 Indeed, the presence of SSTR1 and SSTR2 messenger RNA has been demonstrated in NSCLC lines. 25 Similar sensitivity and specificity of 2 somatostatin analogs in this study favor the idea that binding to SSTR2, rather than SSRT3, is the basis for the detection of NSCLC with Tc-99m depreotide and Tc-99m-EDDA/HYNIC-TOC.
The results of our visual analyses indicate that the 2 analogs offer a good compromise between the sensitivity and specificity for characterization of uncertain pulmonary lesions. The values reported here are in agreement with previously published ranges for both sensitivity (86%-97%) and specificity (51%-80%) of Tc-99m depreotide and Tc-99m-EDDA/HYNIC-TOC in evaluation of solitary pulmonary nodules. 15,26 -29 Although the overall rate of falsenegative findings was rather small in the present study (6 of 60, 10%), they are generally of greater concern than false-positive findings, which often lead to further diagnostic workup. Therefore, possible sources of misclassifying malignant for benign lung lesions need to be considered here.
Two metastases of renal cell carcinoma and 1 adenocarcinoma showed none or only mild uptake (T/Bg 1.2) of Tc-99m depreotide, which prompted their erroneous classification as benign (false-negative finding). Visual and semiquantitative interpretation of no Tc-99m-EDDA/HYNIC-TOC uptake into 2 metastases of rectal adenocarcinoma and 1 lung adenocarcinoma led to 3 additional false-negative findings. Assuming that the renal cell carcinoma has a high expression of SSRT2 and 5, as indicated by T/Bg ratio is 2.69. B, Tc-99m-EDDA/ HYNIC-TOC anterior and posterior WBS show increased focal uptake in the apical part of the right lung (arrows). T/Bg ratio is 2.95. Note the difference in biodistribution of the 2 tracers: higher accumulation of Tc-99m depreotide in the bone marrow (sternum, ribs, and spine) and lower to no accumulation in the heart region (A). The accumulation of Tc-99m-EDDA/HYNIC-TOC in the blood pool of the heart is the same or higher than in the lungs (B).
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In-111-pentetreotide imaging, 30 the somatostatin tracers used in this study should bind to these receptors. However, a recent study with In-111-pentetreotide imaging also reported false-negative results for the metastases of renal cell carcinoma in the lungs, which was ascribed to lower expression of SSRs in the metastatic compared with primary tumor site. 31 The presumed lower density of SSRs in the metastatic renal cell carcinoma may also explain our falsenegative findings. Unfortunately, our results cannot be verified because we are not aware of any publication that used Tc-99m depreotide for imaging of renal cell carcinoma.
Two well-differentiated adenocarcinomas were also false negative on both Tc-99m depreotide and Tc-99m-EDDA/HYNIC-TOC SPECT imaging, and 2 factors should be considered in this context. First, limited data are available concerning the specific SSR expression in adenocarcinomas of the lung, which, if variable, may result in false-negative findings. This assumption is supported by a few anecdotal cases of variably differentiated adenocarcinomas that resulted in false-negative findings on Tc-99m depreotide scintigraphy. 15, 27 Second, the same 2 lesions were rather small (1.2 and 1.3 cm); thus, limited spatial resolution of the gamma camera could also be responsible for false-negative findings. On the other hand, we observed 1 false-positive uptake of Tc-99m depreotide in a pseudoinflammatory lesion and another 1 due to apparent accumulation of Tc-99m-EDDA/HYNIC-TOC in the tuberculoid granuloma (T/Bg 1.3). These results can be explained by the expression of SSRs in activated lymphocytes, inflammatory tissue, and granulomatous tissue constituting benign lesions. 15, 23, 27 We found some difference in the distribution of 2 somatostatin analogs throughout the body, which cannot be ascribed to different affinity to SSRTs. Burggaser et al found up to 5% of microcolloid particles in the Tc-99m depreotide kit (NeoSPECT, CIS bio international, Yvette, Cedex, France). 32 Labeled microcolloid particles that bind to the reticuloendothelial system, such as bone marrow in the spine, ribs, and sternum, allow visualization of these structures on Tc-99m depreotide scintigrams. These colloid particles are not present in the Tc-99m-EDDA/HYNIC-TOC kit (Tektrotyd, Polatom, Warsaw, Poland). The observed difference in blood pool activity of the heart is likely due to the faster plasma clearance of Tc-99m depreotide. 18 However, these differences should not affect visual interpretation of WBS and SPECT images. 22 In spite of differences in distribution, similar diagnostic accuracy of Use of Somatostatin Analog Radiopharmaceuticals the studied somatostatin analogs was affirmed by semiquantitative analysis of T/Bg ratio. Combining WBS and SPECT is now considered a standard protocol for imaging with Tc-99m depreotide and Tc-99m-EDDA/ HYNIC-TOC. 33 It has recently been reported that Tc-99m depreotide WBS may be helpful in evaluation of bone lesions and extraosseous metastases in patients with lung cancer. 34, 35 Although the 2 somatostatin analogs have comparable sensitivity and specificity in this study, SPECT should be preferred over WBS, as it provides better visualization of lung lesions owing to significantly higher T/Bg ratio. 36 Although the positron emission tomography (PET) with F-18 FDG PET has been recognized as a method of choice for characterizing the nature of lung lesions, 37 it requires expensive imaging equipment. Therefore, somatostatin analogs, which are suitable for imaging with conventional gamma cameras, offer a viable alternative.
Study Limitations
Our study has several limitations. First, we avoided exposing patients to higher radiation doses within a short period, and thus did not study patients with both analogs. This concern prompted allocation to 2 independent groups, and such parallel study design somewhat reduced the statistical power. Because the allocation was not formally random, there was a potential for selection bias. To limit its influence, the allocation was based on relevant clinical parameters and done by the investigator who was not involved in the interpretation of findings for a given patient. In retrospect, the composition of 2 groups appears well balanced, which provides confidence in the results of this investigation. The limited spatial resolution of WBS and SPECT is also of concern, when it comes to detection of small lesions. A newly introduced hybrid SPECT/CT system provides more precise anatomic localization and overall better visualization of lung lesions, which is expected to increase the diagnostic yield of scintigraphy. 38 Another limitation is a relatively small sample size that may have influenced the reported false-negative rate (10%), which is generally of greater concern for patient management than false-positive results. Therefore, larger prospective studies are needed to further evaluate the accuracy of somatostatin receptor scintigraphy, especially with regard to false-negative rate.
CONCLUSIONS
This study demonstrates comparable diagnostic value of Tc99m depreotide and Tc-99m-EDDA/HYNIC-TOC for characterizing pulmonary lesions that seem ambiguous on CT. SPECT images provide generally better visualization than WBS. Quantification of tracer uptake did not increase the diagnostic yield over visual interpretation. The overall results suggest that clinicians can rely on both methods with confidence, particularly in the settings where PET is not available. The choice between 2 somatostatin analogs may be driven by other factors such as cost and availability.
